

## PRESS RELEASE

### Evolva's NootkaSHIELD™ insect repellent approved in Hong Kong

Reinach, 11 October 2022 – Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, has received approval for its NootkaSHIELD™ concept from the Hong Kong regulatory authorities as an active ingredient for use in insecticides and insect repellents. The initial market launch of an application as personal repellent spray is targeted for the first quarter of 2023.

The registration in Hong Kong is an important milestone in preparing for further launches in other Asian markets where insect prevalence is high due to tropical climate conditions. The formulations in liquid form, first as a skin-applied repellent followed by other applications, are to be marketed and distributed by a local partner in a multi-channel approach.

The approval in Hong Kong follows the approval of NootkaSHIELD™ as active ingredient in the United States, which Evolva received from the US Environmental Protection Agency (EPA) in August 2020, as well as initial launch activities during 2022 in Singapore which led to first sales in 3Q 2022.

Astrid Schäfer, Head of Innovation and R&D of Evolva, comments: "This initial registration in Hong Kong is testimony to the strength of Evolva's data regarding the safety and efficacy of NootkaSHIELD™ and paves the way for further launches in other Asian markets. We are excited about the perspectives with our initial market tests and the potential these initial launches open up for subsequent extensions in South East Asia and the United States."

#### Important dates

09 March 2023	Full-year 2022 results
18 April 2023	Annual General Meeting

#### Contact

Doris Rudischhauser  
Investor Relations and Corporate Communications  
+41 79 410 81 88  
dorisr@evolva.com

#### About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva's employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at [evolva.com](https://evolva.com) and connect with us on [LinkedIn](#).



For Evolva multimedia content, please visit: [evolva.com/multimedia-library](https://evolva.com/multimedia-library).

#### **Disclaimer**

This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.